Pharmacological activation of the GR is a proven, effective treatment strategy for lymphoid cancers, including acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and multiple myeloma41. This evidence concerns the gene NR3C1 and B-cell chronic lymphocytic leukemia.